vaccinepackaging

Rapid scale-up The project Includes joint investment and tech transfer to prepare segregated and dedicated manufacturing capacity at Catalent’s Bloomington facility in Indiana to prepare for rapid scale-up and cGMP commercial manufacturing of the investigational vaccine candidate. Catalent plans to hire approximately 300 additional employees at the site for this program starting in July to meet operational readiness for 24×7 manufacturing by January 2021. The 875,000 sq.-ft.